Patent: 10,172,922
✉ Email this page to a colleague
Summary for Patent: 10,172,922
| Title: | Rapid-acting insulin compositions |
| Abstract: | The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products. |
| Inventor(s): | Christe; Michael Edward (Pendleton, IN), Hardy; Thomas Andrew (Carmel, IN) |
| Assignee: | Eli Lilly and Company (Indianapolis, IN) |
| Application Number: | 15/259,101 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,172,922
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | June 14, 1996 | ⤷ Start Trial | 2036-09-08 |
| Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | August 06, 1998 | ⤷ Start Trial | 2036-09-08 |
| Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | September 06, 2007 | ⤷ Start Trial | 2036-09-08 |
| Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | June 06, 2017 | ⤷ Start Trial | 2036-09-08 |
| Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | November 15, 2019 | ⤷ Start Trial | 2036-09-08 |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | June 07, 2000 | ⤷ Start Trial | 2036-09-08 |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | January 19, 2001 | ⤷ Start Trial | 2036-09-08 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
